Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolida-tion Therapy as Well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

NCT00850382 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT00850382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00850382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolida-tion Therapy as Well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
Lead sponsor
University of Ulm
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2009
Completion date
November 30, 2015
Enrollment
89 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)